KRT-232: a novel MDM2 inhibitor approach in myelofibrosis

Novel therapies for myelofibrosisПодробнее

BOREAS: KRT-232 in patients with myelofibrosis R/R to JAK inhibitorsПодробнее

KRT‑232: first-in-class MDM2I for myelofibrosis R/R to JAK inhibitor therapyПодробнее

Risk-Adapted Treatment in Myelofibrosis: JAK Inhibitors and Novel Combination TherapiesПодробнее

The latest clinical updates on navtemadlin for the treatment of MPNsПодробнее

Management of Myelofibrosis: JAK Inhibitors and Novel Therapeutics in the Peri-Transplant SettingПодробнее

MDM2 inhibition in MFПодробнее

Phase II study update of navtemadlin in patients with myelofibrosis R/R to ruxolitinibПодробнее

Natural product-like MDM2 inhibitorsПодробнее

JAK2 Inhibition in the Treatment of MyelofibrosisПодробнее

Looking beyond JAK inhibitors: novel targeted therapies and strategies for MPN treatmentПодробнее

Phase I dose-escalation study of the BET inhibitor INCB057643 in R/R myelofibrosisПодробнее

Pacritinib activity against myelofibrosisПодробнее

Myelofibrosis: Emerging JAK2 Inhibitor Combination Treatment StrategiesПодробнее

Early results of PHE885, a novel BCMA-directed CAR-T therapy for the treatment of R/R MMПодробнее

Prolonged idasanutlin treatment causes GI toxicity in PVПодробнее

Inhibiting MDM2 to promote apoptosis in ALLПодробнее

New Drugs for MPNs - Dr. John MascarenhasПодробнее

Promising agents under investigation for the treatment of myelofibrosis with cytopeniaПодробнее